Authors of the systematic review and meta-analysis aimed to determine the all-cause and cause-specific mortality in psoriatic arthritis and ankylosing spondylitis, based on available literature.
The ongoing phase 3 BE MOBILE 2 study compared the efficacy and safety of bimekizumab to placebo in 332 adults with active ankylosing spondylitis.
Researchers assessed the immune response of patients with rheumatoid arthritis and seronegative spondyloarthritis to mRNA COVID-19 vaccination after the first and second dose.
Investigators sought to identify oral clinical manifestations due to oral mucosa changes associated with IBD among patients with spondyloarthritis without a diagnosis of IBD.
The approval was based on data from a phase 3 study which evaluated tofacitinib in adults with active AS who had an inadequate response to at least 2 NSAIDs.
In a case study, Dr de Carvalho describes the successful use of alternative and complementary medicine in a patient with ankylosing spondylitis after cessation of adalimumab therapy.
Authors of a viewpoint discuss the lack of efficacy of anti-IL-23 therapy for axial spondyloarthritis, but the benefits of these medications in improving back pain symptoms induced by axial inflammation in psoriatic arthritis.
Researchers studied the prevalence and 4-year incidence of acute anterior uveitis, inflammatory bowel disease, and psoriasis, and explore the associations between extraskeletal manifestations and clinical disease outcomes in axial spondyloarthritis.
Researchers observed a shared gut microbiota signature for patients with axial spondyloarthritis and its related immune-mediated diseases.
In an abstract presented at ACR Convergence 2021, researchers described the long-term safety profile of upadacitinib in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.